论文部分内容阅读
糖化血红蛋白(HbA1c)用于评价糖尿病患者的血糖控制水平已有数十年的历史,临床现多采用检测空腹、餐后2h血糖或葡萄糖耐量试验来筛查和诊断糖尿病,但许多回顾研究发现,现有检查存在受试者依从性差、需禁食或受饮食等相关影响、缺乏合理筛查标准等缺陷。随着近年来HbA1c检测技术的进步,HbA1c检测用于糖尿病的初筛和诊断已成为一种趋势。2010年美国糖尿病协会《糖尿病临床治疗推荐》增加糖基化血红蛋白(HbA1c≥6.5%)作为糖尿病的诊断标准。现就HbA1c在糖尿病的诊断和初筛中的临床应用及展望等作以下综述。
Glycated hemoglobin (HbA1c) has been used to evaluate glycemic control in diabetics for decades. Clinically, HbA1c has been used to screen and diagnose diabetes in fasting, postprandial 2h blood glucose or glucose tolerance tests. However, many retrospective studies found that HbA1c, There are existing subjects with poor compliance test, the need for fasting or diet-related effects, the lack of a reasonable screening standards and other defects. With the progress of HbA1c detection technology in recent years, screening and diagnosis of HbA1c for diabetes has become a trend. 2010 American Diabetes Association “recommended clinical treatment of diabetes” increased glycosylated hemoglobin (HbA1c ≥ 6.5%) as a diagnostic criteria for diabetes. Now HbA1c in the diagnosis and screening of diabetes in the clinical application and prospects for the following review.